News | June 09, 2023
Croda breaks ground on lipid manufacturing facility in Pennsylvania
Construction will begin this year with the new capacity anticipated by 2025
Construction will begin this year with the new capacity anticipated by 2025
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
The development and deployment of effective vaccines can help to mitigate the impact of pandemics, and we must prioritize research efforts to achieve this objective
One thousand times more soluble than L-cystine at neutral pH
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
India’s efforts are aimed at boosting health at the last mile
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
The need is to focus on an enabling framework to bridge the digital divide across countries specifically amongst low-and-middle-income countries
Subscribe To Our Newsletter & Stay Updated
